Table 1.

Clinical data.

	Control (n = 6) LVEF > 60%	Group (I) (n = 10) LVEF 50–45%	Group (II) (n = 15) LVEF 44–30%	Group (III) (n = 15) LVEF < 30%
Age (y)	32.6 ± 10.8	34 ± 9.39	38.8 ± 7.87	41.13 ± 11.83
Men/women (n)	5/1	8/2	12/3	11/4
NYHA class	—	1.22 ± 0.44	1.6 ± 0.57	2.10 ± 0.47
BMI	22.05 ± 0.92	21.7 ± 1.43	26.58 ± 2.89	25.35 ± 3.88
LV EF [%]	63 ± 4	47.77 ± 2.81	35.80 ± 3.42	22.33 ± 4.06
LV EDD [mm]	51.34 ± 3.74	53.44 ± 1.74	65.13 ± 7.38	71.53 ± 6.65
LV ESD [mm]	30 ± 1.4	34.55 ± 4.74	47.73 ± 8.75	60.13 ± 5.46
ESV [mL]	45 ± 8	52 ± 4.2	124.2 ± 44.76	188.93 ± 49.25
EDV [mL]	102 ± 13.2	105 ± 24.8	182.86 ± 57.9	241.8 ± 79.15
NT-proBNP [pg/mL]	64.4 ± 1.4	78.61 ± 1.3	999.8 ± 1625.1	1709.6 ± 2314.3
Creatinine [µmol/L]	68.9 ± 10.2	72.01 ± 10.5	72.22 ± 13.09	76.46 ± 12.5
Glucose [mmol/L]	5 ± 0.40	5.03 ± 0.45	5.02 ± 0.40	5.51 ± 0.91
Cholesterol [mmol/L]	3.3 ± 1.42	3.33 ± 1.97	5.13 ± 0.58	4.99 ± 1.55
TG [mmol/L]	1.45 ± 0.21	0.85 ± 0.74	1.62 ± 0.77	1.53 ± 0.86
HDL [mmol/L]	1.2 ± 0.81	1.05 ± 0.84	1.39 ± 3.14	1.40 ± 0.56
LDL [mmol/L]	2.12 ± 0.50	2.01 ± 1.39	3.14 ± 0.60	2.45 ± 1.34
Diuretics	—	1	8	14
Digitalis	—	1	4	9
ACE inhibitors	—	2	3	3
β-blockers	—	3	6	5